The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial

Abstract Background Previous studies have shown that monotherapy with apatinib, an oral tyrosine kinase inhibitor, has promising efficacy for treating recurrent or metastatic (RM) nasopharyngeal carcinoma (NPC) patients. In this study, we aimed to assess the efficacy and safety of apatinib combined...

Full description

Bibliographic Details
Main Authors: Lin-Quan Tang, Xiao-Yun Li, Zhi-Ming Li, Zhi-Gang Liu, Miao-Zhen Lin, Huan Zhou, Qi-Wen Yu, Jian Zhou, Chong Zhao, Ze-Bin Chen, Xi-Cheng Wang, Jia-Yu Peng, Qiu-Yan Chen, Wen-Feng Fang, Yun-Peng Yang, Bei Zhang, Liang-Ping Xia, Pi-Li Hu, Wei-Han Hu, Yi-Jie Li, Hai-Qiang Mai, Xiu-Yu Cai
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Medicine
Subjects:
Nasopharyngeal carcinoma
Tyrosine kinase inhibitor
Apatinib
Online Access:https://doi.org/10.1186/s12916-023-02790-1

Internet

https://doi.org/10.1186/s12916-023-02790-1

Similar Items